| Accession |
PRJCA010892 |
| Title |
An Exploratory Clinical Study of GC012F Injection in CD19- and/or BCMA-Positive Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma |
| Relevance |
Medical |
| Data types |
Cytokines, Anti-drug antibody
|
| Organisms |
Homo sapiens
|
| Description |
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and tolerability of GC012F in patients with CD19- and/or BCMA-positive relapsed/refractory B-cell Non-Hodgkin's lymphoma (B-NHL). Primary objectives: To evaluate the safety and tolerability of GC012F in CD19- and/or BCMA-positive relapsed/refractory B-cell non-Hodgkin's lymphoma. |
| Sample scope |
Serum |
| Release date |
2022-07-29 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
min
su (min.su@gracellbio.com)
|
| Organization |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
| Submission date |
2022-07-29 |
